GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...
International drug developer GSK is leaving a massive Rockville research and development facility that was custom-made for a company it acquired. With the move, the company is expanding its presence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback